ERBB2 and breast carcinoma: It has been demonstrated that oncogenic PIK3CA mutations may contribute to more resistance to antibody-based therapeutic trastuzumab and anti-HER2 agent lapatinib (a dual tyrosine kinase inhibitor blocking HER1 and HER2 tyrosine kinase activity) treatment in breast cancer [50,51].